Risk of left atrial appendage thrombus in older patients with atrial fibrillation

被引:3
作者
Gawalko, Monika [1 ]
Budnik, Monika [1 ]
Uzieblo-Zyczkowska, Beata [2 ]
Gorczyca, Iwona [3 ]
Krzesinski, Pawet [2 ]
Scislo, Piotr [1 ]
Kochanowski, Janusz [1 ]
Michalska, Anna [4 ]
Jelonek, Olga [3 ]
Starzyk, Katarzyna [3 ]
Jurek, Agnieszka [2 ]
Kiliszek, Marek [2 ]
Wozakowska-Kaplon, Beata [3 ,4 ]
Gielerak, Grzegorz [2 ]
Filipiak, Krzysztof J. [1 ]
Opolski, Grzegorz [1 ]
Kaplon-Cieslicka, Agnieszka [1 ]
机构
[1] Med Univ Warsaw, Dept Cardiol 1, 1a Banacha St, PL-02097 Warsaw, Poland
[2] Mil Inst Med, Dept Cardiol & Internal Dis, Warsaw, Poland
[3] Swietokrzyskie Cardiol Ctr, Clin Cardiol & Electrotherapy 1, Kielce, Poland
[4] Jan Kochanowski Univ, Fac Med & Hlth Sci, Kielce, Poland
关键词
thromboembolic risk; age; stroke prevention; oral anticoagulation; HEART-FAILURE; ISCHEMIC-STROKE; MANAGEMENT; ANTICOAGULATION; PREVENTION; GUIDELINES; WARFARIN; OUTCOMES; THERAPY; PREDICTORS;
D O I
10.5114/aoms/126028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: We aimed to compare the prevalence of left atrial appendage (LAA) thrombus and its predictors between old and young patients with atrial fibrillation (AF). Material and methods: The study included 1970 patients aged >= 65 (n = 822 (41.7%)) and < 65 (n = 1148 (58.3%)) referred for AF cardioversion or ablation preceded by transoesophageal echocardiography (TEE). Results: Oral anticoagulation (OAC) was prescribed in 799 (97.2%) patients aged >= 65 years and in 1054 (91.8%) of those aged < 65 years (p < 0.001). In patients treated with OAC, those aged >= 65 years less often received vitamin K antagonist (VKA) (267 (33.4%) vs. 416 (39.5%)) and more often non-VKA-OAC (NOAC) (532 (66.6%) vs. 638 (60.5%), p = 0.008, p = 0.008) compared to patients < 65 years. On TEE, LAA thrombus was more often observed in patients aged >= 65 years than those aged < 65 years (63 (7.7%) vs. 46 (4.0%), p < 0.001), with an absolute but not statistically significant difference between patients aged 65-74 and >= 75 years (47 (7.3%) vs. 16 (8.8%), p = 0.528). In patients aged >= 65 years, there was no difference in the prevalence of LAA thrombus between patients treated with VKA and NOAC, in contrast to patients aged < 65 years, in whom such a difference was observed (27 (6.5%) vs. 16 (2.5%), p = 0.002). In multivariate logistic regression, predictors of LAA thrombus in both age groups were older age, non-paroxysmal AF, and heart failure, whereas only in patients aged < 65 years - VKA use, and in those aged >= 65 years - lower glomerular filtration rate and platelet count. Conclusions: Despite OAC use, older patients with AF remain at high risk of LAA thrombus formation. Older age, non-paroxysmal AF, and heart failure are predictors of LAA thrombus, irrespective of age.
引用
收藏
页码:1721 / 1730
页数:10
相关论文
共 45 条
  • [1] Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
    Almutairi, Abdulaali R.
    Zhou, Lili
    Gellad, Walid F.
    Lee, Jeannie K.
    Slack, Marion K.
    Martin, Jennifer R.
    Lo-Ciganic, Wei-Hsuan
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (07) : 1456 - 1478
  • [2] Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry
    Apenteng, Patricia N.
    Gao, Haiyan
    Hobbs, F. D. Richard
    Fitzmaurice, David A.
    [J]. BMJ OPEN, 2018, 8 (01):
  • [3] Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis
    Caldeira, Daniel
    Nunes-Ferreira, Afonso
    Rodrigues, Raquel
    Vicente, Eunice
    Pinto, Fausto J.
    Ferreira, Joaquim J.
    [J]. ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2019, 81 : 209 - 214
  • [4] Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]
  • [5] An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation
    Cardoso, Rhanderson
    Knijnik, Leonardo
    Bhonsale, Aditya
    Miller, Jared
    Nasi, Guilherme
    Rivera, Manuel
    Blumer, Vanessa
    Calkins, Hugh
    [J]. HEART RHYTHM, 2018, 15 (01) : 107 - 115
  • [6] Coleman Craig I, 2019, J Mark Access Health Policy, V7, P1574541, DOI 10.1080/20016689.2019.1574541
  • [7] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [8] The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists
    Domienik-Karlowicz, Justyna
    Tronina, Olga
    Lisik, Wojciech
    Durlik, Magdalena
    Pruszczyk, Piotr
    [J]. CARDIOLOGY JOURNAL, 2020, 27 (06) : 868 - 874
  • [9] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
    Eikelboom, John W.
    Wallentin, Lars
    Connolly, Stuart J.
    Ezekowitz, Mike
    Healey, Jeff S.
    Oldgren, Jonas
    Yang, Sean
    Alings, Marco
    Kaatz, Scott
    Hohnloser, Stefan H.
    Diener, Hans-Christoph
    Franzosi, Maria Grazia
    Huber, Kurt
    Reilly, Paul
    Varrone, Jeanne
    Yusuf, Salim
    [J]. CIRCULATION, 2011, 123 (21) : 2363 - U72
  • [10] Research into practice: management of atrial fibrillation in general practice
    Fitzmaurice, David A.
    Hobbs, F. D. Richard
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2014, 64 (627) : 540 - 542